B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

BETA-3

MOLECULAR TARGET

Beta-3 adrenergic receptor (human)

UniProt: P1394515 compounds

BETA-3 (Beta-3 adrenergic receptor (human)) is targeted by 15 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting BETA-3

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Isoproterenol Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on2.208
2Propranolol1.795
3Bupranolol1.614
4Norepinephrine Precursor of epinephrine that is secreted by1.614
5Carvedilol1.393
6Astemizole Antihistamine drug now withdrawn from1.102
7Bunolol1.102
8Clotrimazole1.102
9Econazole1.102
10Levobunolol1.102
11Miconazole1.102
12Pindolol1.102
13Timolol1.102
14Epinephrine0.691
15Nadolol0.691

About BETA-3 as a Drug Target

BETA-3 (Beta-3 adrenergic receptor (human)) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 15 compounds with documented BETA-3 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

BETA-3 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.